Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

07/12/2021 | 07:00am EDT

Enochian BioSciences, Inc. announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall. The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the ‘gold standard’ animal model to evaluate HBV cure.


ę S&P Capital IQ 2021
All news about ENOCHIAN BIOSCIENCES, INC.
09/13ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure, Financial Statements and Ex..
AQ
09/13ENOCHIAN BIOSCIENCES : Slide Presentation Here
PU
09/13ENOCHIAN BIOSCIENCES : to Present to Investors at the H.C. Wainwright 23rd Annua..
AQ
08/30ENOCHIAN BIOSCIENCES : Distinguished Scientific and Public Health Leaders to Joi..
PU
08/30ENOCHIAN BIOSCIENCES INC : Other Events, Financial Statements and Exhibits (form..
AQ
08/30ENOCHIAN BIOSCIENCES : Distinguished Scientific and Public Health Leaders to Joi..
AQ
08/30Enochian Biosciences, Inc. Appoints Dr. Peter Piot and Dr. Richard Whitley to..
CI
08/23Dr. Anna Suk-Fong Lok, Md to Joins Enochian Biosciences’ Hepatitis B Cure Sci..
CI
08/23ENOCHIAN BIOSCIENCES : Distinguished Scientific and Clinical Leader to Join Enoc..
PU
08/16ENOCHIAN BIOSCIENCES : Entry into a Material Definitive Agreement, Financial Sta..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -11,4 M - -
Net cash 2020 1,11 M - -
P/E ratio 2020 -17,1x
Yield 2020 -
Capitalization 377 M 377 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 10
Free-Float 38,2%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.145.76%377
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850